[go: up one dir, main page]

WO2009069291A1 - Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke - Google Patents

Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke Download PDF

Info

Publication number
WO2009069291A1
WO2009069291A1 PCT/JP2008/003480 JP2008003480W WO2009069291A1 WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1 JP 2008003480 W JP2008003480 W JP 2008003480W WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1
Authority
WO
WIPO (PCT)
Prior art keywords
prophylactic
inhalation
therapeutic composition
tobacco smoke
disease caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/003480
Other languages
French (fr)
Japanese (ja)
Inventor
Satoru Furukawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2009069291A1 publication Critical patent/WO2009069291A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a prophylactic and/or therapeutic composition for chronic obstructive pulmonary disease (COPD) which is a disease caused by the inhalation of tobacco smoke. A composition is prepared, which comprises, as an active ingredient, at least one substance selected from the group consisting of orotic acid, orotidylic acid (a derivative of orotic acid), orotidine and uridine monophosphate (UMP), and inorganic salts and organic salts thereof. In the preparation, it is preferred that the composition be further added with an antioxidative agent, such as glutathione, N-acetylcysteine, coenzyme Q10, α-lipoic acid, vitamin C, vitamin E, polyphenol and carotenoid. The prophylactic and/or therapeutic composition can be administered orally or through inhalation.
PCT/JP2008/003480 2007-11-26 2008-11-26 Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke Ceased WO2009069291A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007305017A JP2011026204A (en) 2007-11-26 2007-11-26 Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke
JP2007-305017 2007-11-26

Publications (1)

Publication Number Publication Date
WO2009069291A1 true WO2009069291A1 (en) 2009-06-04

Family

ID=40678202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003480 Ceased WO2009069291A1 (en) 2007-11-26 2008-11-26 Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke

Country Status (2)

Country Link
JP (1) JP2011026204A (en)
WO (1) WO2009069291A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081604A1 (en) * 2010-12-15 2012-06-21 キリンホールディングス株式会社 Composition containing orotic acid, and process for production thereof
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
WO2018207929A1 (en) * 2017-05-12 2018-11-15 株式会社古川リサーチオフィス Arterial oxygen saturation degree improver
CN115814090A (en) * 2022-11-22 2023-03-21 广州医科大学附属第一医院 Novel medicine target spot for tobacco-induced inflammation
US11890315B2 (en) 2017-11-17 2024-02-06 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
US12097238B2 (en) 2022-01-04 2024-09-24 Renovion, Inc. Aqueous solution comprising a glutathione salt
US12427180B2 (en) 2016-11-17 2025-09-30 Renovion, Inc. Treatment of respiratory tract diseases and infections with ascorbic acid compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2556832B1 (en) * 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease
GB2524831A (en) * 2014-04-04 2015-10-07 Ermes Medical Company Ltd New pharmaceutical use
JP6811983B2 (en) * 2016-08-18 2021-01-13 株式会社古川リサーチオフィス Oral composition having retinal ganglion cell death inhibitory activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505553A (en) * 1996-11-07 2001-04-24 インスパイアー ファーマシューティカルズ，インコーポレイティド Method of treating bronchitis with uridine triphosphate and related compounds
WO2002100409A1 (en) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Antiinflammatoric and antitussive compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505553A (en) * 1996-11-07 2001-04-24 インスパイアー ファーマシューティカルズ，インコーポレイティド Method of treating bronchitis with uridine triphosphate and related compounds
WO2002100409A1 (en) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Antiinflammatoric and antitussive compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Encyclopedic Reference of Molecular Pharmacology", 2004, SPRINGER-VERLAG, pages: 784 - 790 *
ANDERSON C.M. ET AL.: "Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 18, 1997, pages 387 - 392 *
LAZAROWSKI E.R. ET AL.: "Direct Demonstration of Mechanically Induced Release of Cellular UTP and Its Implication for Uridine Nucleotide Receptor Activation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 39, 1997, pages 24348 - 24354 *
PELS RIJCKEN W.R. ET AL.: "Pyrimidine metabolism and sugar nucleotide synthesis in rat liver", BIOCHEMICAL JOURNAL, vol. 266, 1990, pages 777 - 783 *
SAIAG B. ET AL.: "Lack of uptake, release and action of UTP at sympathetic perivascular nerve terminals in rabbit ear artery", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 358, 1998, pages 139 - 145 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081604A1 (en) * 2010-12-15 2012-06-21 キリンホールディングス株式会社 Composition containing orotic acid, and process for production thereof
US11135181B2 (en) 2014-10-28 2021-10-05 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US12427180B2 (en) 2016-11-17 2025-09-30 Renovion, Inc. Treatment of respiratory tract diseases and infections with ascorbic acid compositions
US11331318B2 (en) 2017-05-12 2022-05-17 Furukawa Research Office Co., Ltd. Arterial oxygen saturation degree improver
JPWO2018207929A1 (en) * 2017-05-12 2020-01-23 株式会社古川リサーチオフィス Arterial blood oxygen saturation enhancer
WO2018207929A1 (en) * 2017-05-12 2018-11-15 株式会社古川リサーチオフィス Arterial oxygen saturation degree improver
US11890315B2 (en) 2017-11-17 2024-02-06 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
US12350307B2 (en) 2017-11-17 2025-07-08 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
US12097238B2 (en) 2022-01-04 2024-09-24 Renovion, Inc. Aqueous solution comprising a glutathione salt
US12419932B2 (en) 2022-01-04 2025-09-23 Renovion, Inc. Aqueous solution comprising a glutathione salt
CN115814090A (en) * 2022-11-22 2023-03-21 广州医科大学附属第一医院 Novel medicine target spot for tobacco-induced inflammation
CN115814090B (en) * 2022-11-22 2024-05-24 广州医科大学附属第一医院 Drug targets for tobacco-induced inflammation

Also Published As

Publication number Publication date
JP2011026204A (en) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2009069291A1 (en) Prophylactic and/or therapeutic composition for disease caused by inhalation of tobacco smoke
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
NO20082124L (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
NZ592383A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
WO2007095043A3 (en) Pharmaceutical formulations
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2007114945A3 (en) Compositions and methods for enhancing the antioxidant status of animals
SG156613A1 (en) Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
WO2007093365A3 (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
NO20082047L (en) Slow release composition, process for its preparation and use thereof
WO2008133330A1 (en) Stable solid preparation comprising 4,5-epoxymorphinan derivative
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
NO20074933L (en) Pharmaceutical composition comprising an indolylmaleimide derivative
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP